ENSG00000143970 |
|
prostate adenocarcinoma |
missense_variant |
3.862% (83/2149) |
3 entries |
ENSG00000143970 |
|
prostate carcinoma |
sequence_alteration |
3.756% (16/426) |
3 entries |
ENSG00000143970 |
|
cecum adenocarcinoma |
stop_gained |
4.563% (12/263) |
2 entries |
ENSG00000143970 |
|
esophageal adenocarcinoma |
sequence_alteration |
5.872% (32/545) |
2 entries |
ENSG00000143970 |
|
colorectal adenocarcinoma |
missense_variant |
3.296% (38/1153) |
3 entries |
ENSG00000143970 |
|
melanoma |
conservative_inframe_deletion |
9.655% (14/145) |
1 entry |
ENSG00000143970 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
0.4769% (3/629) |
1 entry |
ENSG00000143970 |
|
lung adenocarcinoma |
sequence_alteration |
1.864% (47/2521) |
6 entries |
ENSG00000143970 |
|
gastric adenocarcinoma |
missense_variant |
1.811% (13/718) |
1 entry |
ENSG00000143970 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
3.529% (3/85) |
1 entry |
ENSG00000143970 |
|
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
3.333% (2/60) |
1 entry |
ENSG00000143970 |
|
clear cell renal carcinoma |
sequence_alteration |
1.534% (22/1434) |
3 entries |
ENSG00000143970 |
|
bladder transitional cell carcinoma |
missense_variant |
4.251% (19/447) |
3 entries |
ENSG00000143970 |
|
cecum adenocarcinoma |
sequence_alteration |
4.563% (12/263) |
2 entries |
ENSG00000143970 |
|
rectal adenocarcinoma |
sequence_alteration |
2.752% (15/545) |
2 entries |
ENSG00000143970 |
|
esophageal squamous cell carcinoma |
missense_variant |
1.316% (9/684) |
4 entries |
ENSG00000143970 |
|
bladder transitional cell carcinoma |
sequence_alteration |
4.251% (19/447) |
1 entry |
ENSG00000143970 |
|
T-cell acute lymphoblastic leukemia |
sequence_alteration |
1.575% (6/381) |
1 entry |
ENSG00000143970 |
|
bile duct adenocarcinoma |
missense_variant |
1.305% (5/383) |
1 entry |
ENSG00000143970 |
|
Merkel cell skin cancer |
missense_variant |
2.151% (2/93) |
1 entry |
ENSG00000143970 |
|
prostate carcinoma |
missense_variant |
3.756% (16/426) |
2 entries |
ENSG00000143970 |
|
lung adenocarcinoma |
missense_variant |
1.864% (47/2521) |
7 entries |
ENSG00000143970 |
|
female breast carcinoma |
sequence_alteration |
2.996% (8/267) |
1 entry |
ENSG00000143970 |
|
pancreatic ductal adenocarcinoma |
sequence_alteration |
4.096% (68/1660) |
2 entries |
ENSG00000143970 |
|
breast carcinoma |
missense_variant |
1.425% (21/1474) |
1 entry |
ENSG00000143970 |
|
lung adenocarcinoma |
stop_gained |
1.864% (47/2521) |
2 entries |
ENSG00000143970 |
|
clear cell renal carcinoma |
stop_gained |
1.534% (22/1434) |
1 entry |
ENSG00000143970 |
|
T-cell acute lymphoblastic leukemia |
stop_gained |
1.575% (6/381) |
1 entry |
ENSG00000143970 |
|
basal cell carcinoma |
missense_variant |
19.12% (13/68) |
2 entries |
ENSG00000143970 |
|
Brain Stem Glioblastoma |
sequence_alteration |
3.571% (2/56) |
1 entry |
ENSG00000143970 |
|
breast ductal adenocarcinoma |
stop_gained |
5.092% (80/1571) |
2 entries |
ENSG00000143970 |
|
urothelial carcinoma |
missense_variant |
4.651% (4/86) |
1 entry |
ENSG00000143970 |
|
melanoma |
stop_gained |
9.655% (14/145) |
2 entries |
ENSG00000143970 |
|
colon adenocarcinoma |
missense_variant |
2.318% (29/1251) |
4 entries |
ENSG00000143970 |
|
hepatocellular carcinoma |
missense_variant |
1.22% (12/984) |
2 entries |
ENSG00000143970 |
|
urothelial carcinoma |
stop_gained |
4.651% (4/86) |
1 entry |
ENSG00000143970 |
|
skin carcinoma |
sequence_alteration |
5.769% (6/104) |
1 entry |
ENSG00000143970 |
|
skin melanoma |
sequence_alteration |
3.365% (39/1159) |
2 entries |
ENSG00000143970 |
|
basal cell carcinoma |
sequence_alteration |
19.12% (13/68) |
2 entries |
ENSG00000143970 |
|
prostate adenocarcinoma |
stop_gained |
3.862% (83/2149) |
2 entries |
ENSG00000143970 |
|
skin melanoma |
stop_gained |
3.365% (39/1159) |
1 entry |
ENSG00000143970 |
|
colorectal adenocarcinoma |
stop_gained |
3.296% (38/1153) |
2 entries |
ENSG00000143970 |
|
T-cell acute lymphoblastic leukemia |
frameshift_variant |
1.575% (6/381) |
2 entries |
ENSG00000143970 |
|
bladder transitional cell carcinoma |
stop_gained |
4.251% (19/447) |
1 entry |
ENSG00000143970 |
|
melanoma |
missense_variant |
9.655% (14/145) |
3 entries |
ENSG00000143970 |
|
squamous cell lung carcinoma |
missense_variant |
1.073% (10/932) |
1 entry |
ENSG00000143970 |
|
gastric adenocarcinoma |
sequence_alteration |
1.811% (13/718) |
1 entry |
ENSG00000143970 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
4.096% (68/1660) |
2 entries |
ENSG00000143970 |
|
cecum adenocarcinoma |
missense_variant |
4.563% (12/263) |
2 entries |
ENSG00000143970 |
|
colon adenocarcinoma |
stop_gained |
2.318% (29/1251) |
2 entries |
ENSG00000143970 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.4769% (3/629) |
1 entry |
ENSG00000143970 |
|
clear cell renal carcinoma |
missense_variant |
1.534% (22/1434) |
3 entries |
ENSG00000143970 |
|
non-small cell lung carcinoma |
missense_variant |
3.125% (3/96) |
2 entries |
ENSG00000143970 |
|
prostate adenocarcinoma |
frameshift_variant |
3.862% (83/2149) |
1 entry |
ENSG00000143970 |
|
esophageal squamous cell carcinoma |
sequence_alteration |
1.316% (9/684) |
1 entry |
ENSG00000143970 |
|
colon adenocarcinoma |
sequence_alteration |
2.318% (29/1251) |
4 entries |
ENSG00000143970 |
|
female breast carcinoma |
missense_variant |
2.996% (8/267) |
2 entries |
ENSG00000143970 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
3.87% (25/646) |
1 entry |
ENSG00000143970 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
0.3606% (3/832) |
1 entry |
ENSG00000143970 |
|
acute myeloid leukemia |
sequence_alteration |
1.087% (11/1012) |
1 entry |
ENSG00000143970 |
|
small cell lung carcinoma |
missense_variant |
2.273% (10/440) |
2 entries |
ENSG00000143970 |
|
prostate adenocarcinoma |
sequence_alteration |
3.862% (83/2149) |
3 entries |
ENSG00000143970 |
|
brain glioblastoma |
frameshift_variant |
0.5872% (7/1192) |
1 entry |
ENSG00000143970 |
|
oral squamous cell carcinoma |
sequence_alteration |
1.136% (3/264) |
2 entries |
ENSG00000143970 |
|
cecum adenocarcinoma |
frameshift_variant |
4.563% (12/263) |
2 entries |
ENSG00000143970 |
|
acute myeloid leukemia |
missense_variant |
1.087% (11/1012) |
1 entry |
ENSG00000143970 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
3.87% (25/646) |
1 entry |
ENSG00000143970 |
|
small cell lung carcinoma |
sequence_alteration |
2.273% (10/440) |
2 entries |
ENSG00000143970 |
|
rectal adenocarcinoma |
frameshift_variant |
2.752% (15/545) |
2 entries |
ENSG00000143970 |
|
skin melanoma |
missense_variant |
3.365% (39/1159) |
2 entries |
ENSG00000143970 |
|
esophageal adenocarcinoma |
missense_variant |
5.872% (32/545) |
2 entries |
ENSG00000143970 |
|
oral squamous cell carcinoma |
missense_variant |
1.136% (3/264) |
3 entries |
ENSG00000143970 |
|
brain glioblastoma |
missense_variant |
0.5872% (7/1192) |
1 entry |
ENSG00000143970 |
|
bladder carcinoma |
missense_variant |
5.348% (30/561) |
1 entry |
ENSG00000143970 |
|
skin melanoma |
conservative_inframe_deletion |
3.365% (39/1159) |
1 entry |
ENSG00000143970 |
|
thyroid carcinoma |
missense_variant |
0.54% (5/926) |
1 entry |
ENSG00000143970 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
2.02% (2/99) |
1 entry |
ENSG00000143970 |
|
chromophobe renal cell carcinoma |
frameshift_variant |
2.041% (3/147) |
1 entry |
ENSG00000143970 |
|
breast ductal adenocarcinoma |
missense_variant |
5.092% (80/1571) |
2 entries |
ENSG00000143970 |
|
colon adenocarcinoma |
frameshift_variant |
2.318% (29/1251) |
2 entries |
ENSG00000143970 |
|
rectal adenocarcinoma |
missense_variant |
2.752% (15/545) |
3 entries |
ENSG00000143970 |
|
melanoma |
sequence_alteration |
9.655% (14/145) |
2 entries |
ENSG00000143970 |
|
pancreatic neuroendocrine tumor |
sequence_alteration |
6.356% (15/236) |
1 entry |
ENSG00000143970 |
|
rectal adenocarcinoma |
stop_gained |
2.752% (15/545) |
2 entries |
ENSG00000143970 |
|
pleomorphic liposarcoma |
missense_variant |
22.22% (2/9) |
2 entries |
ENSG00000143970 |
|
colorectal adenocarcinoma |
sequence_alteration |
3.296% (38/1153) |
2 entries |
ENSG00000143970 |
|
breast ductal adenocarcinoma |
sequence_alteration |
5.092% (80/1571) |
2 entries |
ENSG00000143970 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.667% (3/180) |
2 entries |
ENSG00000143970 |
|
Uterine Carcinosarcoma |
sequence_alteration |
2.703% (4/148) |
1 entry |
ENSG00000143970 |
|
Appendix Adenocarcinoma |
missense_variant |
2.703% (2/74) |
1 entry |
ENSG00000143970 |
|
papillary renal cell carcinoma |
missense_variant |
0.274% (1/365) |
1 entry |
ENSG00000143970 |
|
pancreatic neuroendocrine tumor |
missense_variant |
6.356% (15/236) |
1 entry |
ENSG00000143970 |
|
female breast carcinoma |
frameshift_variant |
2.996% (8/267) |
1 entry |
ENSG00000143970 |
|
Uterine Carcinosarcoma |
missense_variant |
2.703% (4/148) |
1 entry |
ENSG00000143970 |
|
Ampulla of Vater Carcinoma |
sequence_alteration |
1.176% (1/85) |
1 entry |
ENSG00000143970 |
|
colorectal adenocarcinoma |
frameshift_variant |
3.296% (38/1153) |
1 entry |
ENSG00000143970 |
|
chronic lymphocytic leukemia |
frameshift_variant |
1.122% (10/891) |
1 entry |
ENSG00000143970 |
|
neoplasm of mature B-cells |
missense_variant |
1.667% (1/60) |
1 entry |
ENSG00000143970 |
|
Ovarian Granulosa Cell Tumor |
frameshift_variant |
7.143% (1/14) |
1 entry |
ENSG00000143970 |
|
lobular breast carcinoma |
missense_variant |
2.165% (5/231) |
1 entry |
ENSG00000143970 |
|
Uveal Melanoma |
missense_variant |
0.7812% (1/128) |
1 entry |
ENSG00000143970 |
|
Gastrointestinal stromal tumor |
missense_variant |
0.6757% (1/148) |
1 entry |
ENSG00000143970 |
|
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
3.87% (25/646) |
1 entry |
ENSG00000143970 |
|
breast ductal adenocarcinoma |
frameshift_variant |
5.092% (80/1571) |
1 entry |
ENSG00000143970 |
|
Tonsillar Squamous Cell Carcinoma |
sequence_alteration |
11.11% (1/9) |
1 entry |
ENSG00000143970 |
|
brain astrocytoma |
missense_variant |
2.083% (1/48) |
1 entry |
ENSG00000143970 |
|
anaplastic astrocytoma |
missense_variant |
0.7692% (1/130) |
1 entry |
ENSG00000143970 |
|
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
1.667% (3/180) |
1 entry |
ENSG00000143970 |
|
ependymoma |
sequence_alteration |
1.852% (1/54) |
1 entry |
ENSG00000143970 |
|
unspecified peripheral T-cell lymphoma |
sequence_alteration |
5.263% (1/19) |
1 entry |
ENSG00000143970 |
|
bladder carcinoma |
stop_gained |
5.348% (30/561) |
1 entry |
ENSG00000143970 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000143970 |
|
Cortisol-Producing Adrenal Cortex Adenoma |
missense_variant |
0.8065% (1/124) |
1 entry |
ENSG00000143970 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
1.639% (1/61) |
1 entry |
ENSG00000143970 |
|
bladder transitional cell carcinoma |
frameshift_variant |
4.251% (19/447) |
1 entry |
ENSG00000143970 |
|
diffuse gastric adenocarcinoma |
stop_gained |
2.439% (2/82) |
1 entry |
ENSG00000143970 |
|
laryngeal squamous cell carcinoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000143970 |
|
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000143970 |
|
colorectal adenoma |
sequence_alteration |
11.11% (1/9) |
1 entry |
ENSG00000143970 |
|
bile duct adenocarcinoma |
stop_gained |
1.305% (5/383) |
1 entry |
ENSG00000143970 |
|
brain glioblastoma |
sequence_alteration |
0.5872% (7/1192) |
1 entry |
ENSG00000143970 |
|
bile duct adenocarcinoma |
frameshift_variant |
1.305% (5/383) |
1 entry |
ENSG00000143970 |
|
Signet Ring Cell Gastric Adenocarcinoma |
frameshift_variant |
50.0% (1/2) |
1 entry |
ENSG00000143970 |
|
colorectal adenoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000143970 |
|
diffuse gastric adenocarcinoma |
sequence_alteration |
2.439% (2/82) |
1 entry |
ENSG00000143970 |
|
Pancreatic Acinar Cell Carcinoma |
missense_variant |
2.941% (1/34) |
1 entry |
ENSG00000143970 |
|
Ampulla of Vater Carcinoma |
stop_gained |
1.176% (1/85) |
1 entry |
ENSG00000143970 |
|
anaplastic oligodendroglioma |
missense_variant |
1.176% (1/85) |
1 entry |
ENSG00000143970 |
|
Tonsillar Squamous Cell Carcinoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000143970 |
|
neoplasm of mature B-cells |
sequence_alteration |
1.667% (1/60) |
1 entry |
ENSG00000143970 |
|
clear cell renal carcinoma |
frameshift_variant |
1.534% (22/1434) |
1 entry |
ENSG00000143970 |
|
skin carcinoma |
missense_variant |
5.769% (6/104) |
1 entry |
ENSG00000143970 |
|
chronic lymphocytic leukemia |
stop_gained |
1.122% (10/891) |
1 entry |
ENSG00000143970 |
|
nasopharyngeal squamous cell carcinoma |
stop_gained |
1.667% (3/180) |
1 entry |
ENSG00000143970 |
|
carcinoid tumor |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000143970 |
|
gastric intestinal type adenocarcinoma |
sequence_alteration |
3.529% (3/85) |
1 entry |
ENSG00000143970 |
|
adenosquamous lung carcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000143970 |
|
unspecified peripheral T-cell lymphoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000143970 |
|
Signet Ring Cell Gastric Adenocarcinoma |
sequence_alteration |
50.0% (1/2) |
1 entry |
ENSG00000143970 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
0.7407% (1/135) |
1 entry |
ENSG00000143970 |
|
ovarian serous adenocarcinoma |
missense_variant |
0.3606% (3/832) |
1 entry |
ENSG00000143970 |
|
colon adenocarcinoma |
conservative_inframe_deletion |
2.318% (29/1251) |
1 entry |
ENSG00000143970 |
|
bronchoalveolar adenocarcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000143970 |
|
Duodenal Adenocarcinoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000143970 |
|
colorectal adenocarcinoma |
conservative_inframe_deletion |
3.296% (38/1153) |
1 entry |
ENSG00000143970 |
|
squamous cell lung carcinoma |
stop_gained |
1.073% (10/932) |
1 entry |
ENSG00000143970 |
|
anaplastic oligodendroglioma |
sequence_alteration |
1.176% (1/85) |
1 entry |
ENSG00000143970 |
|
Major Salivary Gland Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000143970 |
|
prostate carcinoma |
frameshift_variant |
3.756% (16/426) |
1 entry |
ENSG00000143970 |
|
Appendix Adenocarcinoma |
sequence_alteration |
2.703% (2/74) |
1 entry |